ScreenerHero

EOLSEvolus, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · evolus.com
8.390USD-2.44%Mkt Cap: 554.16M $P/E: —

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap554.16M $
Enterprise Value671.16M $
Revenue (TTM)316.49M $
Gross Profit197.11M $
Net Income (TTM)-51.64M $
Revenue/Share4.855 USD
Last Price8.390 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees353
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS30052C1071
Valuation
P/E (Trailing)—
P/E (Forward)30.25
PEG—
EV/EBITDA-57.25
EV/Revenue2.12
P/S1.74
P/B-17.84
EPS (TTM)-0.51
EPS (Forward)0.28
52W Range
3.86094% of range8.690
52W High8.690 USD
52W Low3.860 USD
Profitability
Gross Margin66.33%
Oper. Margin-3.92%
EBITDA Margin-3.70%
Profit Margin-17.38%
ROE223.50%
ROA-22.86%
Growth
Revenue Growth21.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-42.27M $
CapEx (TTM)8.45M $
FCF Margin-0.37%
FCF Yield-0.21%
Net Debt119.63M $
Net Debt/EBITDA-10.21
Balance Sheet
Debt/Equity-6.71
Current Ratio1.70
Quick Ratio1.09
Book Value/Sh-0.4680 USD
Cash/Share0.6840 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.00 USD
Upside (mean)+78.8%
Target Range12.00 USD – 20.00 USD
$12.00+78.8% to mean$20.00
# Analysts6
Ownership
Shares Out.66.05M
Float51.01M
Insiders14.64%
Institutions73.67%
Short Interest
Short Ratio7.8d
Short % Float8.54%
Short % Out.8.43%
Shares Short5.57M
Short (prev mo.)6.02M
Technical
SMA 506.785 (+23.7%)
SMA 2005.945 (+41.1%)
Beta1.36
S&P 52W Chg18.16%
Avg Vol (30d)915.60K
Avg Vol (10d)1.12M
Technical Indicators
RSI (14)67.4
MACD0.5450
MACD Signal0.3720
MACD Hist.+0.1730
BB Upper9.095 USD
BB Middle7.028 USD
BB Lower4.961 USD
BB Width58.82%
ATR (14)0.4419 USD
Vol Ratio (20d)0.59x